Only a small number of barrier-enhancing factors have been discovered to specifically increase barrier integrity, enhance vessel stability, and make vessels resistant to fluid leakage. Here, Fahey et al. present DEVDIL-36β as a cytokine promoter of vascular integrity in the CNS, with barrier-enhancing properties through upregulation of junctional components.
The device is also used in selected neurological cases where accurate signal detection and responsive stimulation are critical to managing symptoms over time. Its application forms part of a broader treatment pathway rather than a standalone intervention.
Implantation is performed using minimally invasive techniques and typically takes three to five hours. The approach avoids large surgical incisions and supports shorter recovery periods, allowing patients to resume daily activities more quickly.
Rather than marking a single milestone, the continued use of this technology reflects KFSHRC’s integration of artificial intelligence into routine neurological care, where adaptability and long-term management are central to patient outcomes.
RIYADH, SAUDI ARABIA, December 28, 2025 /EINPresswire.com/ — At King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh, artificial intelligence enabled brain implants are used as part of advanced care for patients with neurological conditions, including Parkinson’s disease and selected movement disorders.
The implant functions by continuously analyzing brain signals and responding to abnormal activity through targeted electrical stimulation. This adaptive approach allows treatment to adjust in real time based on the patient’s neural patterns, reducing reliance on fixed stimulation settings and limiting the need for frequent manual recalibration.
In clinical practice, the technology has supported improved symptom control for patients whose conditions require precise neuromodulation. As treatment progresses, some patients have been able to reduce their dependence on medication under clinical supervision, while maintaining daily function and stability.
Scientists have long suspected that a small population of cells survives treatment and regenerates the tumor. These “cancer stem cells” are thought to resist conventional therapies, allowing the disease to return even after the visible tumor has been removed.
Previous attempts to identify gastric cancer stem cells using other protein markers, such as CD44 or CD133, yielded inconsistent results. These markers often appeared on healthy cells as well or did not fully account for tumor behaviour.
The team discovered that AQP5 reliably marks the cancer stem cells in gastric tumors. Aquaporins are proteins that form channels in cell membranes to control the movement of water into and out of cells. While AQP5 was previously known to mark stem cells in healthy gastric tissue, this study shows it also identifies the specific cells responsible for driving tumor growth, spread, and recurrence.
Importantly, AQP5 does more than simply mark these cells; it actively contributes to their aggressive behavior.
The researchers found that cells with AQP5 were capable of forming new tumors, while cells without AQP5 rarely did so. Most significantly, when they used a targeted method to eliminate only the AQP5-expressing cells, tumors stopped growing or shrank entirely and did not recur. This held true even for cancers that had spread to other organs.
Scientists have identified the specific cells responsible for gastric cancer’s tendency to return after treatment. The study also demonstrated that eliminating these cells stops tumors from growing, even in advanced disease that has spread to other organs.
Blood Test #7 in 2025 Supplements Analysis [ ]
This year, the International Diabetes Federation (IDF) officially recognized a fifth form of diabetes, after decades of controversy. It’s now urging other health authorities, like the World Health Organization (WHO), to follow suit.
Type 5 diabetes is rarely discussed or researched, and yet it is thought to impact up to 25 million people worldwide, especially those in low-and middle-income nations where access to medical care is limited.
It was first described in 1955 in Jamaica, then forgotten about for many years. Even once it was acknowledged by the WHO in the 1980s, the diagnosis created controversy.
A study by researchers at the Federal University of São Carlos (UFSCar) in Brazil, in partnership with University College London (UCL) in the United Kingdom, concluded that the combination of abdominal fat and muscle loss increases the risk of death by 83%, compared to people without these conditions.
This combination is so dangerous that it identifies an even greater problem: sarcopenic obesity. This condition is characterized by loss of muscle mass while gaining fat throughout the body. It is a difficult condition to diagnose, and it is related to loss of autonomy and a worsening quality of life in older adults. It is also known as frailty syndrome and is associated with an increased risk of falls and other comorbidities.
“In addition to assessing the risk of death associated with abdominal obesity and low muscle mass, we were able to prove that simple methods can be used to detect sarcopenic obesity. This is important because the lack of consensus on diagnostic criteria for this disease makes it difficult to detect and treat,” says Tiago da Silva Alexandre, a professor in the Department of Gerontology at UFSCar and one of the authors of the study.
Frequent tanning bed users may have up to an eight times greater risk for melanoma than people considered at high risk for melanoma who don’t use tanning beds, according to a new study that also showed how tanning beds alter melanoma-linked DNA on the molecular level and damage areas of skin not usually exposed to the sun.
A case-control cohort study of patients considered at high risk for melanoma finds that tanning bed users have higher rates of melanoma and disease with significantly more mutations.